Skip to content

Released Nov 5, 2020, after the close

10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051301

Q3 2020 · 10-Q
Revenue$7.56M+211.2% vs Q3 2019+38.3% vs Q2 2020
Net Income-$58.68MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.68N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$31,487,000N/M
Operating Cash Flowderived-$30,733,000N/M
Free Cash Flowderived-$31,687,000N/M
Margins · derived
Operating margin-416.6%+699.9 pt vs Q3 2019
Net margin-776.4%+319.0 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$7.56M$2.43M$1.03M$1.03M
Net Income-$58.68M-$26.61M-$16.78M-$10.68M
EPS Diluted-$0.68-$0.40-$0.31-$0.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR